Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. Issue 5 (7th September 2020)

• Record Type: Journal Article
• Authors: Pogue-Geile, Katherine L; Song, Nan; Serie, Daniel J; Wang, Ying; Gavin, Patrick G; Kim, Rim S; Tanaka, Noriko; Fumagalli, Debora; Taniyama, Yusuke; Li, Zhuo; Rastogi, Priya; Swain, Sandra M; Mamounas, Eleftherios P; Geyer, Charles E; Wolmark, Norman; Lucas, Peter C; Paik, Soonmyung; Thompson, E Aubrey
• Is Part Of: JNCI cancer spectrum. Volume 4:Issue 5(2020)
• Publication Date: 2020-09-07
• DOI: 10.1093/jncics/pkaa058
• Languages: English
• ISSNs: 2515-5091

Abstract

Abstract: Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N = 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then NCCTG investigators assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, estrogen receptor/progesterone receptor status, tumor size, and grade. Hazard ratios and 2-sided P values for recurrence-free survival of the predicted large- (n = 387), moderate- (n = 401), and no-benefit (n = 104) groups, based on the 8-gene signature were 0.47 (95% CI = 0.31 to 0.73, P < .001), 0.60 (95% CI = 0.39 to 0.92, P = .02), and 1.54 (95% CI = 0.59 to 4.02, P = .38), respectively ( P interaction = .02), providing validation of the 8-gene signature in an independent study.